<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639262</url>
  </required_header>
  <id_info>
    <org_study_id>07P.381</org_study_id>
    <secondary_id>2006-58</secondary_id>
    <nct_id>NCT00639262</nct_id>
  </id_info>
  <brief_title>Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors</brief_title>
  <official_title>Phase I Study of the Combination of Sorafenib and Radiation Therapy -/+ Temozolomide for the Treatment of Patients With Brain Metastases and Primary Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sorafenib™ has the potential to inhibit tumor growth, tumor angiogenesis , and enhance&#xD;
      radiation response. This study will test the combination of Sorafenib™ and radiation therapy&#xD;
      with or without temozolomide to determine tolerance of the combined treatments. Defining safe&#xD;
      dosing of Sorafenib™ in this combination therapy will be achieved.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard of care for patients with brain metastatic malignancies is to receive&#xD;
      radiation therapy alone, while the standard of care for patients with high grade primary&#xD;
      brain malignancies, astrocytomas, is to receive to receive concurrent temozolomide with&#xD;
      radiation therapy. In this phase I study, based on the range of efficacy of kinase inhibitors&#xD;
      and its ability to cross the blood-brain barrier we will conduct two parallel studies. The&#xD;
      first is to combine sorafenib and radiation therapy for the treatment of patients with brain&#xD;
      metastases and the second is to combine sorafenib with temozolomide for primary brain tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of Sorafenib</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>To determine the maximum tolerated dose (MTD) and a recommended phase II dose (RP2D) of Sorafenib and radiotherapy -/+ temozolomide patients with malignancies of the brain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>Response rate (in those patients with measurable disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of 1-year Recurrence</measure>
    <time_frame>1 year post-treatment</time_frame>
    <description>Determine if an increase in urinary VEGF and MMP levels, from the end of treatment to a patient's 1-month follow-up examination, is predictive of 1-year recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Toxicity of Sorafenib</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>To evaluate the safety and toxicity profile of Sorafenib in combination with radiation therapy -/+ temozolomide</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Brain Metastases</condition>
  <condition>Primary Brain Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Brain Metastasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib and Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Gliomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib and Radiotherapy, plus Temozolomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)</description>
    <arm_group_label>Cohort 1 - Brain Metastasis</arm_group_label>
    <arm_group_label>Cohort 2 - Gliomas</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>For Cohort 2 - Gliomas only.</description>
    <arm_group_label>Cohort 2 - Gliomas</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiation Therapy (XRT)</description>
    <arm_group_label>Cohort 1 - Brain Metastasis</arm_group_label>
    <arm_group_label>Cohort 2 - Gliomas</arm_group_label>
    <other_name>XRT</other_name>
    <other_name>Radiation therapy</other_name>
    <other_name>radiation oncology</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients requiring a minimum 2-week course of radiation therapy&#xD;
&#xD;
          2. Age &gt; or = 18&#xD;
&#xD;
          3. All tumors of the central nervous system, or metastasis to the central nervous system.&#xD;
&#xD;
          4. Measurable disease preferred but not required for eligibility&#xD;
&#xD;
          5. Histologically or cytologically documented evidence of malignancy (for infratentorial&#xD;
             and supratentorial glioma patients only).&#xD;
&#xD;
          6. Radiographic evidence of brain metastasis&#xD;
&#xD;
          7. ECOG performance status of 0 or 1&#xD;
&#xD;
          8. Life expectancy of &gt; or = 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients receiving chemotherapy or other investigational drugs must be discontinued 14&#xD;
             days prior to enrollment.&#xD;
&#xD;
          2. Cardiac disease: Congestive heart failure &gt; class II NYHA. Patients must not have&#xD;
             unstable angina (anginal symptoms at rest) or new onset angina (began within the last&#xD;
             3 months) or myocardial infarction within the past 6 months.&#xD;
&#xD;
          3. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.&#xD;
&#xD;
          4. Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic&#xD;
             pressure &gt; 90 mmHg, despite optimal medical management.&#xD;
&#xD;
          5. Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.&#xD;
&#xD;
          6. Active clinically serious infection &gt; CTCAE Grade 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Dicker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>March 13, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Brain Metastases</keyword>
  <keyword>Brain Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

